8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 2, 2021

Commission File Number: 0-24260

AMEDISYS, INC.

(Exact Name of Registrant as specified in its Charter)

Delaware	11-3131700
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	AMED	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

SECTION 2 — FINANCIAL INFORMATION

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On November 2, 2021, the Company issued a press release (the “Press Release”) announcing its financial results for the three and nine-month periods ended September 30, 2021. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information presented in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless we specifically state that the information is to be considered “filed” under the Exchange Act or specifically incorporate it by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act.

SECTION 7 – REGULATION FD

ITEM 7.01. REGULATION FD DISCLOSURE

Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.

In addition, a copy of the supplemental slides which will be discussed during the Company’s earnings call at 11:00 a.m. ET on Wednesday, November 3, 2021 is attached to this report as Exhibit 99.2 and incorporated herein by reference.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

99.1	Press release dated November 2, 2021 announcing the Company’s results for the three and nine-month periods ended September 30, 2021 (furnished only)
99.2	Supplemental slides provided in connection with the third quarter 2021 earnings call of the Company (furnished only)
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.
(Registrant)
By:	/s/ Scott G. Ginn
	Scott G. Ginn
	Executive Vice President and Chief Financial Officer
	(Principal Financial Officer)
DATE:	November 2, 2021

EX-99.1

Exhibit 99.1

AMEDISYS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS

UPDATES 2021 GUIDANCE

BATON ROUGE, Louisiana (November 2, 2021) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2021.

Three-Month Periods Ended September 30, 2021 and 2020

• Net service revenue increased $9.4 million to $553.5 million compared to $544.1 million in 2020.

• Net income attributable to Amedisys, Inc. of $45.0 million compared to $72.0 million (inclusive of a $24.0 million income tax benefit related to executive stock option exercise) in 2020.

• Net income attributable to Amedisys, Inc. per diluted share of $1.37 compared to $2.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.

Adjusted Quarterly Results*

• Adjusted EBITDA of $72.4 million compared to $75.7 million in 2020.

• Adjusted net service revenue of $553.5 million compared to $544.1 million in 2020.

• Adjusted net income attributable to Amedisys, Inc. of $50.5 million compared to $74.6 million (inclusive of a $24.0 million income tax benefit related to executive stock option exercise) in 2020.

• Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.53 compared to $2.24 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.

Nine-Month Periods Ended September 30, 2021 and 2020

• Net service revenue increased $134.0 million to $1,654.8 million compared to $1,520.8 million in 2020.

• Net income attributable to Amedisys, Inc. of $175.0 million compared to $138.5 million (inclusive of a $24.0 million income tax benefit related to executive stock option exercise) in 2020.

• Net income attributable to Amedisys, Inc. per diluted share of $5.30 compared to $4.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.

Adjusted Year to Date Results*

• Adjusted EBITDA of $234.8 million compared to $195.4 million in 2020.

• Adjusted net service revenue of $1,648.3 million compared to $1,520.8 million in 2020.

• Adjusted net income attributable to Amedisys, Inc. of $157.5 million compared to $153.9 million (inclusive of a $24.0 million income tax benefit related to executive stock option exercise) in 2020.

• Adjusted net income attributable to Amedisys, Inc. per diluted share of $4.77 compared to $4.63 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.

* See pages 3 and 16 - 18 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

1

Updated 2021 Guidance

COVID-19 has continued to impact the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and Contessa. We are basing our guidance on our current operating environment. COVID-19 continues to evolve in both the disease itself as well as disruptions to the healthcare systems and the economy. Any future regulations or government interventions, spike in clinicians and business development staff on quarantine, staffing shortages due to current and proposed federal, state and local vaccine mandates, reduction in elective procedures, change in patient behavior and further decline in senior living occupancy could impact our ability to achieve this guidance.

Based upon the above discussion, our updated 2021 guidance is as follows:

• Adjusted net service revenue is anticipated to be in the range of $2.200 billion to $2.205 billion.

• Adjusted EBITDA is anticipated to be in the range of $296 million to $298 million.

• Adjusted diluted earnings per share is anticipated to be in the range of $5.88 to $5.93 based on an estimated 33.0 million shares outstanding.

This guidance excludes the effects of any future acquisitions, if any are made.

Paul B. Kusserow, Chairman and Chief Executive Officer stated, “Though COVID-19 continues to impact all of our lines of business, I am very proud of the efforts of the nearly 21,000 Amedisys employees and thank them for their continued dedication and tireless work throughout this quarter and for the results their work produced. Our operating environment continues to change in real-time and yet we have been able to grow Home Health and Hospice admissions. We have made significant progress on recovering our Hospice Business Development staff and remain very confident in our ability to continue to expand this group, translating into further admissions growth. Though it is hard to predict when the impacts of COVID-19 will truly subside, we remain very excited about all of the opportunity ahead of us. We are well positioned to capitalize on the aging demographics of the U.S. population; our industry leading quality scores make us a provider of choice for those that want to be cared for in their homes; and via our acquisition of Contessa, we have assembled a group of assets that truly differentiate Amedisys from our peers. It is a time unlike any other to be in our spaces and tackling the challenges of COVID-19 has, and continues to, energize our entire organization. My enthusiasm for the future of Amedisys has never been stronger.”

We urge caution in considering the current trends and 2021 guidance disclosed in this press release. The home health, hospice, personal care and high acuity care industries are highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com.

2

Earnings Call and Webcast Information

Amedisys will host a conference call on Wednesday, November 3, 2021, at 11:00 a.m. ET to discuss its third quarter results. To participate on the conference call, please call before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through December 3, 2021 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID #13724253.

A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.

Non-GAAP Financial Measures

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted other operating income, defined as other operating income excluding certain items; (4) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. excluding certain items; and (5) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

Additional Information

Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice, personal care and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering our patients to manage a chronic disease; or hospice care at the end of life. More than 2,900 hospitals and 78,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees in 527 care centers within 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 418,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.

We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

Forward-Looking Statements

When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, the impact of current and proposed federal, state and local vaccine mandates, including potential staff shortages, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or

3

establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Contact:	Investor Contact:	Media Contact:
	Amedisys, Inc.	Amedisys, Inc.
	Nick Muscato	Kendra Kimmons
	Senior Vice President, Finance	Vice President, Marketing & Communications
	(615) 928- 5452	(225) 299-3720
	IR@amedisys.com	kendra.kimmons@amedisys.com

4

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share data)

(Unaudited)

	For the Three-Month Periods Ended September 30,						For the Nine-Month Periods Ended September 30,
	2021			2020			2021			2020
Net service revenue	$	553,485		$	544,070		$	1,654,795		$	1,520,814
Other operating income		(4	)		4,812			13,300			27,592
Cost of service, excluding depreciation and amortization		310,294			297,668			916,188			878,633
General and administrative expenses:
Salaries and benefits		119,373			123,146			349,533			330,329
Non-cash compensation		4,397			7,124			17,860			19,758
Other		55,158			49,348			158,995			142,616
Depreciation and amortization		7,487			8,283			21,763			19,955
Operating expenses		496,709			485,569			1,464,339			1,391,291
Operating income		56,772			63,313			203,756			157,115
Other income (expense):
Interest income		—			31			49			258
Interest expense		(2,730	)		(2,692	)		(6,734	)		(8,675	)
Equity in earnings from equity method investments		1,444			1,435			3,932			2,399
Gain (loss) on equity method investments		—			—			31,092			(2,980	)
Miscellaneous, net		490			122			1,253			662
Total other (expense) income, net		(796	)		(1,104	)		29,592			(8,336	)
Income before income taxes		55,976			62,209			233,348			148,779
Income tax (expense) benefit		(10,731	)		10,202			(57,192	)		(9,175	)
Net income		45,245			72,411			176,156			139,604
Net income attributable to noncontrolling interests		(239	)		(430	)		(1,131	)		(1,147	)
Net income attributable to Amedisys, Inc.	$	45,006		$	71,981		$	175,025		$	138,457
Basic earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders	$	1.38		$	2.20		$	5.36		$	4.26
Weighted average shares outstanding		32,607			32,662			32,658			32,469
Diluted earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders	$	1.37		$	2.16		$	5.30		$	4.16
Weighted average shares outstanding		32,899			33,260			33,021			33,267

5

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share data)

	September 30, 2021 (unaudited)			December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents	$	124,458		$	81,808
Restricted cash		3,750			1,549
Patient accounts receivable		274,570			255,145
Prepaid expenses		16,080			10,217
Other current assets		14,024			13,265
Total current assets		432,882			361,984
Property and equipment, net of accumulated depreciation of $100,407 and $95,024		20,381			23,719
Operating lease right of use assets		100,028			93,440
Goodwill		1,188,054			932,685
Intangible assets, net of accumulated amortization of $20,309 and $22,973		118,084			74,183
Deferred income taxes		10,111			47,987
Other assets		68,105			33,200
Total assets	$	1,937,645		$	1,567,198
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	41,649		$	42,674
Payroll and employee benefits		155,123			146,929
Accrued expenses		154,264			166,192
Provider relief fund advance		58,535			60,000
Current portion of long-term obligations		13,225			10,496
Current portion of operating lease liabilities		31,553			30,046
Total current liabilities		454,349			456,337
Long-term obligations, less current portion		434,781			204,511
Operating lease liabilities, less current portion		67,723			61,987
Other long-term obligations		31,991			33,622
Total liabilities		988,844			756,457
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding		—			—
Common stock, $0.001 par value, 60,000,000 shares authorized; 37,659,284 and 37,470,212 shares issued; and 32,590,775 and 32,814,278 shares outstanding		38			38
Additional paid-in capital		720,875			698,287
Treasury stock, at cost 5,068,509 and 4,655,934 shares of common stock		(420,665	)		(319,092	)
Retained earnings		605,016			429,991
Total Amedisys, Inc. stockholders’ equity		905,264			809,224
Noncontrolling interests		43,537			1,517
Total equity		948,801			810,741
Total liabilities and equity	$	1,937,645		$	1,567,198

6

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING

(Amounts in thousands, except statistical information)

(Unaudited)

	For the Three-Month Periods Ended September 30,						For the Nine-Month Periods Ended September 30,
	2021			2020			2021			2020
Cash Flows from Operating Activities:
Net income	$	45,245		$	72,411		$	176,156		$	139,604
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		7,487			8,283			21,763			19,955
Non-cash compensation		4,397			7,124			17,860			19,758
Amortization and impairment of operating lease right of use assets		10,479			10,591			30,181			29,149
(Gain) loss on disposal of property and equipment		(72	)		17			(64	)		(77	)
(Gain) loss on equity method investments		—			—			(31,092	)		2,980
Write-off of other comprehensive income		—			—			—			(15	)
Deferred income taxes		12,013			1,274			34,729			(2,762	)
Equity in earnings from equity method investments		(1,444	)		(1,435	)		(3,932	)		(2,399	)
Amortization of deferred debt issuance costs/debt discount		237			216			669			653
Return on equity method investments		1,585			1,175			4,268			3,919
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable		5,149			(2,511	)		(17,638	)		6,486
Other current assets		(9,779	)		(24,748	)		(6,219	)		(28,217	)
Other assets		(886	)		584			(938	)		(91	)
Accounts payable		5,338			4,825			(1,192	)		(1,627	)
Accrued expenses		(7,736	)		(2,396	)		(9,363	)		25,594
Other long-term obligations		(49	)		17,735			(1,785	)		38,481
Operating lease liabilities		(9,417	)		(9,211	)		(27,372	)		(25,576	)
Operating lease right of use assets		(780	)		(851	)		(2,304	)		(2,775	)
Net cash provided by operating activities		61,767			83,083			183,727			223,040
Cash Flows from Investing Activities:
Proceeds from sale of deferred compensation plan assets		101			73			126			94
Proceeds from sale of property and equipment		98			—			140			80
Purchases of property and equipment		(2,244	)		(1,294	)		(5,187	)		(2,995	)
Investments in technology assets		(147	)		—			(147	)		—
Investments in equity method investees		—			—			—			(875	)
Proceeds from sale of equity method investment		—			—			—			17,876
Acquisitions of businesses, net of cash acquired		(262,369	)		—			(264,872	)		(299,723	)
Net cash used in investing activities		(264,561	)		(1,221	)		(269,940	)		(285,543	)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options		1,083			3,123			1,706			6,070
Proceeds from issuance of stock to employee stock purchase plan		1,061			914			3,022			2,600
Shares withheld to pay taxes on non-cash compensation		(9,750	)		(47,788	)		(16,694	)		(54,172	)
Noncontrolling interest distribution		(459	)		(300	)		(1,253	)		(672	)
Proceeds from borrowings under term loan		290,312			—			290,312			—
Proceeds from borrowings under revolving line of credit		111,500			7,500			500,700			432,000
Repayments of borrowings under revolving line of credit		(141,500	)		(97,500	)		(551,700	)		(357,000	)
Principal payments of long-term obligations		(501	)		(2,685	)		(5,893	)		(7,360	)
Debt issuance costs		(2,792	)		—			(2,792	)		—
Purchase of company stock		(10,805	)		—			(84,879	)		—
Provider relief fund advance		207			(10,000	)		(1,465	)		60,000
Net cash provided by (used in) financing activities		238,356			(146,736	)		131,064			81,466
Net increase (decrease) in cash, cash equivalents and restricted cash		35,562			(64,874	)		44,851			18,963
Cash, cash equivalents and restricted cash at beginning of period		92,646			180,327			83,357			96,490
Cash, cash equivalents and restricted cash at end of period	$	128,208		$	115,453		$	128,208		$	115,453

7

	For the Three-Month Periods Ended September 30,				For the Nine-Month Periods Ended September 30,
	2021		2020		2021		2020
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	1,565	$	1,610	$	3,479	$	4,902
Cash paid for income taxes, net of refunds received	$	16,815	$	22,137	$	25,482	$	30,290
Cash paid for operating lease liabilities	$	10,197	$	10,062	$	29,676	$	28,351
Cash paid for finance lease liabilities	$	492	$	497	$	1,509	$	1,483
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	$	14,192	$	10,982	$	34,881	$	29,876
Right of use assets obtained in exchange for finance lease liabilities	$	287	$	335	$	814	$	822
Reductions to right of use assets resulting from reductions to operating lease liabilities	$	279	$	360	$	1,183	$	767
Days revenue outstanding		43.5		40.0		43.5		40.0

(1) Our calculation of days revenue outstanding, net is derived by dividing our ending patient accounts receivable at September 30, 2021 and 2020 by our average daily net patient service revenue for the three-month periods ended September 30, 2021 and 2020, respectively.

8

AMEDISYS, INC. AND SUBSIDIARIES

SEGMENT INFORMATION

(Amounts in millions, except statistical information)

(Unaudited)

Segment Information - Home Health

	For the Three-Month Periods Ended September 30,
	2021			2020
Financial Information (in millions):
Medicare	$	228.2		$	222.2
Non-Medicare		110.4			103.8
Net service revenue		338.6			326.0
Other operating income		—			2.6
Cost of service		190.1			180.0
Gross margin		148.5			148.6
Other operating expenses		82.4			78.8
Depreciation and amortization		1.1			1.0
Operating income	$	65.0		$	68.8
Same Store Growth (1):
Medicare revenue		2	%		5	%
Non-Medicare revenue		6	%		4	%
Total admissions		1	%		5	%
Total volume (2) (6)		1	%		6	%
Key Statistical Data - Total (3):
Admissions		86,732			85,578
Recertifications (6)		46,919			46,186
Total volume (6)		133,651			131,764
Medicare completed episodes		78,318			77,552
Average Medicare revenue per completed episode (4)	$	2,969		$	2,886
Medicare visits per completed episode (5)		13.8			14.4
Visiting Clinician Cost per Visit	$	94.24		$	89.10
Clinical Manager Cost per Visit	$	9.85		$	8.91
Total Cost per Visit	$	104.09		$	98.01
Visits		1,826,505			1,836,895

9

	For the Nine-Month Periods Ended September 30,
	2021			2020
Financial Information (in millions):
Medicare	$	684.4		$	619.0
Non-Medicare		332.1			300.8
Net service revenue		1,016.5			919.8
Other operating income		7.3			17.7
Cost of service		563.5			543.8
Gross margin		460.3			393.7
Other operating expenses		243.8			226.7
Depreciation and amortization		3.3			2.9
Operating income	$	213.2		$	164.1
Same Store Growth (1):
Medicare revenue		10	%		(4	%)
Non-Medicare revenue		10	%		2	%
Total admissions		8	%		(1	%)
Total volume (2)(6)		6	%		1	%
Key Statistical Data - Total (3):
Admissions		265,933			245,880
Recertifications (6)		136,744			132,811
Total volume (6)		402,677			378,691
Medicare completed episodes		232,838			221,848
Average Medicare revenue per completed episode (4)	$	2,962		$	2,811
Medicare visits per completed episode (5)		14.0			15.2
Visiting Clinician Cost per Visit	$	91.94		$	88.64
Clinical Manager Cost per Visit	$	9.54		$	9.10
Total Cost per Visit	$	101.48		$	97.74
Visits		5,553,423			5,563,992

(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

(2) Total volume includes all admissions and recertifications.

(3) Total includes acquisitions, start-ups and denovos.

(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the transition to PDGM effective January 1, 2020 and the suspension of sequestration effective May 1, 2020.

(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.

(6) Prior year amounts have been recast to conform to the current year calculation.

10

Segment Information - Hospice

	For the Three-Month Periods Ended September 30,
	2021			2020
Financial Information (in millions):
Medicare	$	187.8		$	189.0
Non-Medicare		9.7			10.7
Net service revenue		197.5			199.7
Other operating income		—			1.7
Cost of service		107.6			104.1
Gross margin		89.9			97.3
Other operating expenses		49.5			47.8
Depreciation and amortization		0.7			0.6
Operating income	$	39.7		$	48.9
Same Store Growth (1):
Medicare revenue		(1	%)		3	%
Hospice admissions		1	%		9	%
Average daily census		(5	%)		—	%
Key Statistical Data - Total (2):
Hospice admissions		13,292			13,026
Average daily census		13,272			13,953
Revenue per day, net	$	161.74		$	155.57
Cost of service per day	$	88.06		$	81.05
Average discharge length of stay		94			101

11

	For the Nine-Month Periods Ended September 30,
	2021			2020
Financial Information (in millions):
Medicare	$	556.2		$	516.5
Non-Medicare		30.7			29.7
Net service revenue		586.9			546.2
Other operating income		6.0			8.9
Cost of service		314.4			293.1
Gross margin		278.5			262.0
Other operating expenses		144.4			127.4
Depreciation and amortization		2.0			1.7
Operating income	$	132.1		$	132.9
Same Store Growth (1):
Medicare revenue		—	%		4	%
Hospice admissions		3	%		3	%
Average daily census		(4	%)		1	%
Key Statistical Data - Total (2):
Hospice admissions		39,650			35,755
Average daily census		13,282			12,841
Revenue per day, net	$	161.87		$	155.23
Cost of service per day	$	86.68		$	83.29
Average discharge length of stay		95			98

(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

(2) Total includes acquisitions, start-ups and denovos.

12

Segment Information - Personal Care

	For the Three-Month Periods Ended September 30,
	2021		2020
Financial Information (in millions):
Medicare	$	—	$	—
Non-Medicare		15.9		18.4
Net service revenue		15.9		18.4
Other operating income		—		0.5
Cost of service		11.7		13.5
Gross margin		4.2		5.4
Other operating expenses		2.6		3.2
Depreciation and amortization		0.1		—
Operating income	$	1.5	$	2.2
Key Statistical Data - Total:
Billable hours		558,227		673,161
Clients served		8,697		10,153
Shifts		240,736		280,470
Revenue per hour	$	28.44	$	27.33
Revenue per shift	$	65.95	$	65.59
Hours per shift		2.3		2.4

	For the Nine-Month Periods Ended September 30,
	2021		2020
Financial Information (in millions):
Medicare	$	—	$	—
Non-Medicare		49.9		54.8
Net service revenue		49.9		54.8
Other operating income		—		1.0
Cost of service		37.4		41.7
Gross margin		12.5		14.1
Other operating expenses		8.8		9.5
Depreciation and amortization		0.2		0.1
Operating income	$	3.5	$	4.5
Key Statistical Data - Total:
Billable hours		1,774,965		2,067,958
Clients served		11,597		14,057
Shifts		759,242		896,141
Revenue per hour	$	28.11	$	26.51
Revenue per shift	$	65.71	$	61.18
Hours per shift		2.3		2.3

13

Segment Information - High Acuity Care

	For the Three-Month Periods Ended September 30,
	2021			2020
Financial Information (in millions):
Medicare	$	—		$	—
Non-Medicare		1.5			—
Net service revenue		1.5			—
Other operating income		—			—
Cost of service		0.9			—
Gross margin		0.6			—
Other operating expenses		3.9			—
Depreciation and amortization		0.5			—
Operating income	$	(3.8	)	$	—
Key Statistical Data - Total:
Full risk admissions		46			—
Limited risk admissions		188			—
Total admissions		234			—
Direct medical loss ratio		52.6	%		—
Number of joint ventures		8			—
Market penetration		31	%		—
Patient satisfaction		92	%		—

	For the Nine-Month Periods Ended September 30,
	2021			2020
Financial Information (in millions):
Medicare	$	—		$	—
Non-Medicare		1.5			—
Net service revenue		1.5			—
Other operating income		—			—
Cost of service		0.9			—
Gross margin		0.6			—
Other operating expenses		3.9			—
Depreciation and amortization		0.5			—
Operating income	$	(3.8	)	$	—
Key Statistical Data - Total:
Full risk admissions		46			—
Limited risk admissions		188			—
Total admissions		234			—
Direct medical loss ratio		52.6	%		—
Number of joint ventures		8			—
Market penetration		31	%		—
Patient satisfaction		92	%		—

14

Segment Information - Corporate

	For the Three-Month Periods Ended September 30,
	2021		2020
Financial Information (in millions):
Other operating expenses	$	40.5	$	49.9
Depreciation and amortization		5.1		6.7
Total operating expenses	$	45.6	$	56.6

	For the Nine-Month Periods Ended September 30,
	2021		2020
Financial Information (in millions):
Other operating expenses	$	125.5	$	129.2
Depreciation and amortization		15.8		15.2
Total operating expenses	$	141.3	$	144.4

15

AMEDISYS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES

(Amounts in thousands)

(Unaudited)

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”) Reconciliation:

	For the Three- Month Periods Ended September 30,						For the Nine- Month Periods Ended September 30,
	2021			2020			2021			2020
Net income attributable to Amedisys, Inc.	$	45,006		$	71,981		$	175,025		$	138,457
Add:
Income tax expense (benefit)		10,731			(10,202	)		57,192			9,175
Interest expense, net		2,730			2,661			6,685			8,417
Depreciation and amortization		7,487			8,283			21,763			19,955
Certain items (1)		6,858			3,494			(24,440	)		20,843
Interest component of certain items (1)		(451	)		(558	)		(1,437	)		(1,450	)
Adjusted EBITDA (2) (7)	$	72,361		$	75,659		$	234,788		$	195,397

Adjusted Net Service Revenue Reconciliation:

	For the Three- Month Periods Ended September 30,				For the Nine- Month Periods Ended September 30,
	2021		2020		2021			2020
Net service revenue	$	553,485	$	544,070	$	1,654,795		$	1,520,814
Add:
Certain items (1)		—		—		(6,541	)		—
Adjusted net service revenue (3) (7)	$	553,485	$	544,070	$	1,648,254		$	1,520,814

Adjusted Other Operating Income Reconciliation:

	For the Three- Month Periods Ended September 30,						For the Nine- Month Periods Ended September 30,
	2021			2020			2021			2020
Other operating income	$	(4	)	$	4,812		$	13,300		$	27,592
Add:
Certain items (1)		4			(4,812	)		(13,300	)		(27,592	)
Adjusted other operating income (4) (7)	$	—		$	—		$	—		$	—

Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:

	For the Three- Month Periods Ended September 30,				For the Nine- Month Periods Ended September 30,
	2021		2020		2021			2020
Net income attributable to Amedisys, Inc.	$	45,006	$	71,981	$	175,025		$	138,457
Add:
Certain items (1)		5,474		2,585		(17,495	)		15,424
Adjusted net income attributable to Amedisys, Inc. (5) (7)	$	50,480	$	74,566	$	157,530		$	153,881

16

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:

	For the Three- Month Periods Ended September 30,				For the Nine- Month Periods Ended September 30,
	2021		2020		2021			2020
Net income attributable to Amedisys, Inc. common stockholders per diluted share	$	1.37	$	2.16	$	5.30		$	4.16
Add:
Certain items (1)		0.17		0.08		(0.53	)		0.46
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share (6) (7)	$	1.53	$	2.24	$	4.77		$	4.63

(1) The following details the certain items for the three and nine-month periods ended September 30, 2021 and 2020:

Certain Items:

	For the Three-Month Period Ended September 30, 2021			For the Nine-Month Period Ended September 30, 2021
	(Income) Expense			(Income) Expense
Certain Items Impacting Net Service Revenue:
Contingency accrual	$	—			(6,541	)
Certain Items Impacting Other Operating Income:
CARES Act & State COVID-19 grants		4			(13,300	)
Certain Items Impacting Cost of Service:
COVID-19 costs		3,513			16,457
Certain Items Impacting Operating Expenses:
Acquisition and integration costs		2,757			6,249
COVID-19 costs		199			576
Pre-acquisition legal settlement		—			1,825
Certain Items Impacting Total Other Income (Expense):
Interest component of certain items		451			1,437
Other (income) expense, net		(66	)		(31,143	)
Total	$	6,858		$	(24,440	)
Net of tax	$	5,474		$	(17,495	)
Diluted EPS	$	0.17		$	(0.53	)

	For the Three-Month Period Ended September 30, 2020			For the Nine-Month Period Ended September 30, 2020
	(Income) Expense			(Income) Expense
Certain Items Impacting Other Operating Income:
CARES Act & State COVID-19 grants	$	(4,812	)	$	(27,592	)
Certain Items Impacting Cost of Service:
COVID-19 costs		4,389			27,399
Severance - reductions in staffing levels		(550	)		4,633
Certain Items Impacting Operating Expenses:
Acquisition and integration costs		3,626			9,561
COVID-19 costs		322			1,385
Severance - reductions in staffing levels		—			271
Certain Items Impacting Total Other Income (Expense):
Interest component of certain items		558			1,450
Other (income) expense, net		(39	)		3,736
Total	$	3,494		$	20,843
Net of tax	$	2,585		$	15,424
Diluted EPS	$	0.08		$	0.46

17

(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.

(3) Adjusted net service revenue is defined as net service revenue excluding certain items as described in footnote 1.

(4) Adjusted other operating income is defined as other operating income excluding certain items as described in footnote 1.

(5) Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.

(6) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.

(7) Adjusted EBITDA, adjusted net service revenue, adjusted other operating income, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.

18

EX-99.2

Amedisys Third Quarter 2021 Earnings Call Supplemental Slides November 3rd, 2021 Exhibit 99.2

This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events. Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031. We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law. www.amedisys.com NASDAQ: AMED We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business and clinical operations and control processes, and SEC filings. Forward-looking statements

Our Key Areas of Focus Strategic areas of focus and progress made during Q3’21 Home Health*: Total same store admissions +1%, Total same store volume +1% Hospice: Admissions +1% (+5% sequentially), ADC -5% Personal Care: Billable hours / quarter -17%. Personal Care Network drove ~$500K in revenue to Home Health and Hospice via care coordination 1 Organic Growth Quality: Amedisys Oct’20 release STARS score of 4.33 (SHP: 4.5 STARS) 99% of care centers at 4+ Stars based on internal calculation 44 Amedisys care centers rated at 5 Stars in the Oct’20 Release Hospice quality – outperforming industry average in all hospice item set (HIS) categories 3 Clinical Initiatives Focusing on optimizing RN / LPN & PT / PTA staffing ratios. Current LPN Ratio: 47.9% (vs. 46.7% in 3Q’20) Current PTA Ratio: 53.3% (vs. 49.6% in 3Q’20) 4 Capacity and Productivity Closed the acquisition of Contessa Health adding tech-enabled, risk-bearing, higher-acuity services to our product offering Contessa signed JV agreement with Henry Ford Health System expanding Hospital at Home footprint to Detroit Closed the acquisition of a CON license for Home Health access in Westchester County, NY Closed on the acquisition of VNA (Home Health and Hospice) 5 M&A 2 Recruiting / Retention Targeting industry leading employee retention amongst all employee categories YTD Overall Voluntary Turnover 18.3% vs. 18.9% YTD 2020 Focus on Business Development hiring and turnover, particularly in Hospice +39 (523) Hospice BD FTE’s since Q2’21 +20 (844) Home Health BD FTE’s since Q2’21 *Note: Home Health same store volume is defined as admissions plus recertifications 2021 Reimbursement Final Home Health industry rule net +1.9% increase No-Pay RAP effective 1/1/21 Final Hospice industry rule net +2.4% increase (effective 10/1/20) 2022 Reimbursement Proposed Home Health industry rule net +1.7% increase Expansion of HHVBP to all 50 states beginning 1/1/22 Final Hospice industry rule net +2.0% increase (effective 10/1/21) 6 Regulatory

Highlights and Summary Financial Results (Adjusted): 3Q 2021(1) Home Health total same store volume +1%, total same store admissions +1%; Hospice same store admissions +1%; Margin pressure driven by Hospice ADC decline & labor costs The financial results for the three-month periods ended September 30, 2020 and September 30, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Same Store volume – Includes admissions and recertifications. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments. Q3’20 free cash flow includes payroll tax deferrals. Medicare sequestration suspended 5/1/20. Growth Metrics: Total Admissions: 234 Number of JV’s: 8 Other Statistics: Patient Satisfaction: 92% High Acuity Care Adjusted Financial Results Growth Metrics: Billable hours/quarter: -17% Clients served: -14% Other Statistics: Revenue per hour: +4% Cost per hour: +6% Personal Care Same Store Volume (3): Admissions: +1% ADC: -5% Other Statistics: Revenue per Day: $161.74 (+4.0%) Cost per day: $87.10 (+8.9%) Hospice Home Health Same Store (2)(3) : Total Volume: +1% Total Admissions: +1% Other Statistics: Revenue per Episode(5): $2,969 (+2.9%) Total Cost per Visit: $102.83 (+6.2%) Amedisys Consolidated Revenue Growth: +2% EBITDA: $72M (-4%) EBITDA Margin: 13.1% (-80 bps) EPS: $1.53 (-32%) non-cash tax benefit from executive stock option exercise in prior year ($0.72 benefit) Amedisys Consolidated Amedisys Consolidated Balance Sheet & Cash Flow Net debt: $386.9M Net Leverage ratio: 1.2x Revolver availability: $519.9M CFFO: $61.8M Free cash flow (4): $59.1M DSO: 43.5 (vs. Q4’20 of 40.2 and up 0.8 days since Q2) $ in Millions, except EPS 3Q20 3Q21 % Change Sequential FY 2019 FY 2020 Home Health 326 338.6 3.9% #REF! 1,256.4000000000001 1,249.174 Hospice 199.7 197.5 -1.1% #REF! 623.20000000000005 750.14400000000001 Personal Care 18.399999999999999 15.9 -0.13586956521739121 #REF! 82 72.200999999999993 High Acuity Care 0 1.5 Total Revenue $544.1 $553.5 1.7% #REF! $1,961.6000000000001 $2,071.5189999999998 Gross Margin % 0.46 0.44600000000000001 #REF! 0.41399999999999998 0.44600000000000001 Adjusted EBITDA 75.7 72.400000000000006 -4.4% #REF! 225.3 273.5 0.13900000000000001 0.13080397470641375 #REF! 0.115 0.13200000000000001 Adjusted EPS $2.2400000000000002 $1.53 -0.31696428571428575 #REF! $4.4000000000000004 $6.11 Free cash flow (4) $79.2 $59.1 -0.25378787878787878 #REF! $192.8 $273.5

Medicare FFS: Reimbursed over a 30-day period of care Private Episodic: MA and Commercial plans who reimburse us over a 30-day period of care, majority of which range from 95% - 100% of Medicare rates Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed Hospice Per Day Reimbursement: Routine Care: Patient at home with symptoms controlled ~97% of the Hospice care AMED provides, in line with overall hospice industry provision of care Continuous Care: Patient at home with uncontrolled symptoms Inpatient Care: Patient in facility with uncontrolled symptoms Respite Care: Patient at facility with symptoms controlled Home Health: 328 care centers; 34 states & D.C. Hospice: 177 care centers; 34 states Personal Care: 14 care centers; 3 states High Acuity Care: 8 Joint Ventures; 6 states; 24 referring hospitals Total AMED: 527 care centers; 38 states and D.C. Our Revenue Sources: 3Q’21

Home Health and Hospice Segment (Adjusted) – 3Q 2021(1) Revenue per Episode up 2.9% (+1.9% rate increase effective 1/1/2021) Y/Y CPV up $5.98 (+6.2%, primarily due to an increase in contractor utilization, new hire pay and raises) Visits per Episode decreased 0.6 Home Health Highlights Same store admit growth +1% Net revenue per day +4.0% (primarily due to +2.4% Hospice rate update effective 10/1/2020, favorable revenue adjustments and improvements in mix) Hospice Highlights The financial results for the three-month periods ended September 30, 2020 and September 30, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Pre-Corporate EBITDA does not include any corporate G&A expenses. Same store information represents the percent change in volume or admissions for the period as a percent of the volume or admissions of the prior period. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. Average Medicare revenue per completed episode reflects the transition to PDGM effective Jan. 1, 2020 and the suspension of sequestration effective May 1, 2020. Home Health total volume growth +1%; Hospice Admit Growth +1% HOME HEALTH $ in Millions 3Q20 3Q21 2020 Medicare 222.2 228.2 847.30399999999997 Non-Medicare 103.8 110.4 401.87099999999998 Home Health Revenue $326 $338.6 $1,249.175 Gross Margin % 0.45400000000000001 0.44500000000000001 0.435 Pre-Corporate EBITDA (2) $69.5 $68.400000000000006 $236.7 0.21319018404907975 0.20200826934435914 0.19 Operating Statistics Same Store Growth (3)(4) Total Volume 0.06 0.01 0.02 Total Admissions 0.05 0.01 0.01 Medicare Revenue per Episode (5) $2,886 $2,969 $2,836 Medicare Recert Rate 0.36299999999999999 0.35499999999999998 0.36899999999999999 Total Cost per visit $96.85 $102.83 $95.59

General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A is relatively flat; total G&A as a percentage of revenue decreased 50 basis points Increases related to the Contessa acquisition, a slowdown in prior year spend related to COVID-19, raises, the addition of resources to support growth and higher recruiting fees were offset by lower incentive compensation costs Total G&A as a percentage of revenue increased 110 bps sequentially The financial results for the three-month periods ended September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021 and September 30, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Adjusted G&A expenses do not include depreciation and amortization. Impacted by COVID-19, acquisitions and investments to drive volume growth $ in Millions 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 Home Health Segment - Total 70.7 67.400000000000006 68 68.900000000000006 69.3 70 68.099999999999994 68.8 71.2 71.400000000000006 74 75.599999999999994 76.3 75.8 71.316999999999993 78.616 80.504999999999995 79.956999999999994 81.3 82.370999999999995 % of HH Revenue 0.26300000000000001 0.252 0.254 0.255 0.25600000000000001 0.248 0.2397043294614572 0.23300000000000001 0.23400000000000001 0.23 0.23200000000000001 0.24299999999999999 0.24099999999999999 0.25 0.246 0.24099999999999999 0.24399999999999999 0.24299999999999999 0.23300000000000001 0.24299999999999999 Hospice Segment - Total 17.399999999999999 18 18 19 19 20.5 19.899999999999999 21.4 22.9 29 34.799999999999997 35.6 37.799999999999997 38.700000000000003 40.4 47.79 47.884 46.334000000000003 48.4 49.536000000000001 % of HSP Revenue 0.21199999999999999 0.21099999999999999 0.215 0.21 0.19800000000000001 0.20854526958290948 0.20452209660842754 0.20699999999999999 0.21099999999999999 0.21099999999999999 0.219 0.219 0.23 0.22900000000000001 0.22800000000000001 0.23899999999999999 0.23499999999999999 0.24199999999999999 0.253 0.251 Personal Care Segment - Total 2.2000000000000002 2.9 3.3000000000000003 3 3 3.1 3.2 3 3.2 3.1 3.1 3 3 3.3 3.1 3.0150000000000001 2.9809999999999999 3.0830000000000002 3.0830000000000002 2.6219999999999999 % of PC Revenue 0.20599999999999999 0.22800000000000001 0.24399999999999999 0.21 0.219 0.17299999999999999 0.17877094972067042 0.158 0.14899999999999999 0.155 0.14899999999999999 0.14599999999999999 0.14899999999999999 0.17499999999999999 0.17499999999999999 0.16400000000000001 0.17199999999999999 0.182 0.18099999999999999 0.16500000000000001 High Acuity Care Segment - Total 2.2000000000000002 0.22800000000000001 0.24399999999999999 0.21 0.219 3.1 3.2 3 3.2 3.1 3.1 3 3 3.3 3.1 0 0 0 0 3.8210000000000002 % of HAC Revenue 0.20599999999999999 0.22800000000000001 0.24399999999999999 0.21 0.219 0.17299999999999999 0.17877094972067042 0.158 0.14899999999999999 0.155 0.14899999999999999 0.14599999999999999 0.14899999999999999 0.17499999999999999 0.17499999999999999 -% -% -% -% 2.552 Total Corporate Expenses 29 28.9 27.3 28.400000000000002 25.8 29 29.200000000000003 30.2 31.8 35.6 35.700000000000003 35.9 36.6 36.6 36.6 46.247999999999998 42.817 41.448999999999998 38.1 37.700000000000003 % of Total Revenue 0.08 7.9% 7.7% 7.6% 6.8% 7.3% 7.3% 7.2% 7.3% 7.6% 7.2% 7.3% 7.3% 7.5% 7.5% 8.5% 7.8% 7.7% 6.8% 6.8% Total 119.3 117.20000000000002 116.6 119.30000000000001 117.1 122.6 120.4 123.39999999999999 129.1 139.1 147.6 150.1 153.69999999999999 154.4 151.41699999999997 175.66899999999998 174.18700000000001 170.82299999999998 170.88299999999998 175.95 % of Total Revenue 0.33 0.32100000000000001 0.32100000000000001 0.318 0.308 0.308 0.3015276734284999 0.29599999999999999 0.29699999999999999 0.29699999999999999 0.29599999999999999 0.30299999999999999 0.307 0.314 0.312 0.32300000000000001 0.316 0.318 0.307 0.318 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 Salary and Benefits 13.8 13.700000000000001 13.9 14.1 13.6 15.6 14.9 16.7 18.2 19.600000000000001 20.6 20.799999999999997 20.9 20 21 28.3 25 23.4 22 22.05 24.2 24.2 25.5 Other 12.4 11.8 11 11.3 9.5 10.199999999999999 11.6 10.199999999999999 10 11.4 11.3 10.9 11.4 12.4 11 13.2 13.2 12.7 11.6 12.808 -4.5999999999999996 -4.2 0.5 Corp. G&A Subtotal 26.200000000000003 25.5 24.9 25.4 23.1 25.799999999999997 26.5 26.9 28.2 31 31.900000000000002 31.699999999999996 32.299999999999997 32.4 32 41.5 38.200000000000003 36.099999999999994 33.6 34.858000000000004 19.600000000000001 20 Non-cash comp 2.8 3.4 2.4 3 2.7 3.2 2.7 3.3 3.6 4.5999999999999996 3.8 4.2 4.3 4.2 4.5999999999999996 4.7 4.5999999999999996 5.3 4.5 2.7549999999999999 Adjusted Corporate G&A 29.000000000000004 28.9 27.299999999999997 28.4 25.8 28.999999999999996 29.2 30.2 31.8 35.6 35.700000000000003 35.9 36.599999999999994 36.6 36.6 46.2 42.800000000000004 41.399999999999991 38.1 37.713000000000008 35.6 36.6 11.400000000000002 12.400000000000002

Components 3Q’20 2Q’21 3Q’21 YoY Variance Detail Initiatives Salaries $64.81 $65.02 $67.58 $2.77 YoY increase due to higher fixed new hire pay due to the timing of hires and planned wage increases (new hire pay = $2.06; raises = $1.00) Sequential increase due to the same drivers, partially offset by a lesser impact of planned wage increases and an additional holiday in Q3 Staffing mix optimization, productivity and scheduling improvement initiatives in place to help overcome salary increases Contractors $3.69 $5.10 $4.96 $1.27 YoY increase driven by additional staffing needs due to COVID-19, turnover and growth (4% of visits in 2021 vs 3% in 2020) Focused efforts on filling positions with full-time clinicians Benefits $12.59 $13.18 $13.16 $0.57 YoY increase due to the impact of COVID-19 on health insurance costs (lower utilization in prior year and increased costs in current year due to high-cost claimants) Focus on cost containment and spend optimization with specific focus on high-cost claims Transportation & Supplies $6.85 $6.78 $7.28 $0.43 YoY increase due to higher utilization of wound care related supplies and increase in fuel costs Focus on vendor pricing and spend optimization *Visiting Clinician CPV $87.94 $90.08 $92.98 $5.04 Clinical Managers $8.91 $9.31 $9.85 $0.94 Fixed cost associated with non-visiting clinicians YoY increase driven by additional staff and planned wage increases Unit cost reduced as volume increases Total CPV $96.85 $99.39 $102.83 $5.98 Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted YOY Total CPV impacted by planned wage increases, new hire pay, higher contractor utilization, and higher health insurance costs *Note: Direct comparison with industry competitors CPV calculation $87.94 $90.08 $92.98

Driving Top Line Growth Home Health total volume, Hospice admissions and ADC, as well as Personal Care billable hours lagging due to prolonged COVID-19 impacts related to Delta variant (staffing challenges, increase in clinician quarantine and unexpected increase in hospice discharge rate) Home Health Total Volume Hospice Growth Personal Care Total Hours / Quarter

Industry Leading Quality Scores Note: Top Competitor Avg weighted by CCN count and includes LHC, Kindred, AFAM, EHC and BKD Metric OCT 19 Release JAN 20 Release APR 20 Release Oct 20 Release Quality of Patient Care 4.28 4.27 4.26 4.33 Entities at 4+ Stars 88% 86% 86% 92% Metric OCT 19 Release JAN 20 Release APR 20 Release Oct 20 Release Patient Satisfaction Star 3.97 3.71 3.79 4.28 Performance Over Industry +6% +6% +6% +7% Quality of Patient Care (QPC) Patient Satisfaction (PS) Amedisys maintains a 4-Star average in the Oct 2020 HHC preview with 92% of our providers (representing 95% of care centers) at 4+ Stars and 61% of our providers (representing 65% of care centers) at 4.5+ Stars 26 Amedisys providers (representing 44 care centers) rated at 5 Stars in the Oct 2020 HHC preview. CMS will hold the Oct 2020 HHC data constant (i.e., freeze the data) until the Jan 2022 HHC release.

Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Hospice Compare HIS and CAHPS reporting currently “frozen” and will resume reporting in Feb 2022

Debt and Liquidity Metrics Net leverage ~1.2x Net debt defined as total debt outstanding ($452.8M) less cash ($65.9M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($312.9M). Liquidity defined as the sum of cash balance and available revolving line of credit. Cash per 9/30/21 10-Q less Provider relief fund advance ($58.5M). Outstanding Debt As of: 9/30/21 Pro Forma for Contessa Adjustments as of 6/30/21 Pro Forma for Contessa Adjustments and Under New Credit Facility as of 6/30/21 42460 Adjustments Pro Forma Adjustments Pro Forma Outstanding Revolver 0 250 250 0 0 450 -New TLA Outstanding Term Loan 450 450 0 450 -450 -term Promissory Notes 0.8 Finance Leases 2 2 0 2 0 - RC #REF! Total Debt Outstanding 452.8 250 702 0 452 -250 -purchase price #REF! Less: Deferred Debt Issuance Costs -4.8 0 -4.8 0 -4.8 -250 =remaining cash Total Debt - Balance Sheet 448 250 697.2 0 447.2 #REF! #REF! Total Debt Outstanding 452.8 250 702 0 452 #REF! Less Cash (4) -65.900000000000006 0 -65.900000000000006 250 184.1 Net Debt (1) 386.9 250 636.1 250 636.1 Leverage Ratio (net) (2) 1.2364972834771493 2.0329178651326303 2.0329178651326303 #REF! #REF! Credit Facility As of: 9/30/21 Pro Forma for Contessa Adjustments as of 6/30/21 Pro Forma for Contessa Adjustments and Under New Credit Facility as of 6/30/21 Term Loan 450 0 450 275 450 #REF! Revolver Size 550 0 550 0 550 #REF! Borrowing Capacity 1,000 0 1,000 275 1,000 #REF! Revolver Size 550 0 550 0 550 Outstanding Revolver 0 -,250 -,250 0 0 #REF! Letters of Credit -30.1 0 -30.1 0 -30.1 #REF! Available Revolver 519.9 -,250 269.89999999999998 30 519.9 38.9 Plus Cash (4) 65.900000000000006 0 65.900000000000006 -,250 -,184.1 1.0x Total Liquidity (3) 585.79999999999995 -,250 335.79999999999995 40.299999999999997 335.79999999999995 386.9 312.89999999999998 1.2364972834771493

Cash Flow Statement Highlights (1) 2020 includes benefits of payroll tax deferral (COVID-19 relief). Total payroll tax deferral of ~$55.4M (half due in December 2021 and half due in December 2022). Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. $ in Millions Q214 Q414 FY14 2Q15 4Q15 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 GAAP Net Income #REF! #REF! #REF! #REF! 12.9 11.4 8.9 15.2 4.53 14.66 -3.71 27.3 33.5 31.5 27.7 31.6 34 34.299999999999997 28 32 35.1 72.411000000000001 45.6 50.3 80.599999999999994 45.2 Changes in working capital #REF! #REF! #REF! 9.6 6.7 5.6 -8.1 -7.3 15.8 -11 -2 2.1 20.100000000000001 17.399999999999999 -25.3 12.6 -17.2 33.799999999999997 -47.5 71.3 -24.83 34.5 -18.3 -9.1 -7 Depreciation and amortization #REF! #REF! #REF! #REF! 1.1000000000000001 1.6 4.4000000000000004 4.54 4.1900000000000004 3.98 3.6 3.1 3.2 3.4 2.9 5.2 4.4000000000000004 6 5.3 6.3 8.2840000000000007 8.8000000000000007 7.6 6.7 7.5 Non-cash compensation, includes 401(k) match expense #REF! #REF! #REF! #REF! #REF! 6.1 6.5 5.74 6.7 6.6 6.1 6.9 7.3 9 7.8 9.1999999999999993 9.6 9.1999999999999993 6.7 7.1230000000000002 7 7.3 6.2 4.4000000000000004 Deferred income taxes #REF! #REF! #REF! #REF! -0.1 1.2 9.4 9.44 -1.86 9.6 34.950000000000003 2.9 6.2 5.8 5.4 3.3 2.6 11.9 -4.3 1.2 -5.3 1.274 -23.8 7.4 15.3 12 Other 0.1 1.1000000000000001 -11.1 1.2 1.9 -0.3 1 2.8 -1.4 -2.9 4.9000000000000004 2.1 5.8 19.8 18.82 -6.2 -0.3 -31.7 -0.3 107278 Cash flow from operations #REF! #REF! #REF! #REF! 27.6 20.400000000000002 25.5 27.14 7.51 38.89 32.220000000000006 40.299999999999997 50.70000000000001 68.5 63.999999999999986 20.100000000000005 59.300000000000004 47.5 75.199999999999989 6 133.9 83.081999999999994 65.899999999999991 53.999999999999993 68 61.800000000000004 70000 177278 Capital expenditures - routine #REF! #REF! #REF! #REF! #REF! 5.5 5.9 -2.4 -1.4 -0.3 -1.2 -1.3 -0.1 -3.2 -0.8 -1.2 -0.3 -1.2 -1 -1.2 -0.3 -1.2 -2.4 -1.6 -1 -2.2000000000000002 Required debt repayments #REF! #REF! #REF! #REF! #REF! 6.4 5.6 -1.3 -1.3 -1.6 -1.3 -2.8 0 -0.6 -0.4 -0.6 -1.7 -1.5 -1.8 -1.6 -3.1 -2.7 -2.9 -2.7 -2.7 -0.5 Free cash flow #REF! #REF! #REF! #REF! -0.9 0 0 23.44 4.8099999999999996 36.99 29.720000000000006 36.200000000000003 50.600000000000009 64.7 62.79999999999999 18.300000000000004 57.300000000000004 44.8 72.399999999999991 3.1999999999999997 130.5 79.181999999999988 60.599999999999994 49.699999999999989 64.3 59.1 Capital Deployment Acquisitions -63.3 -3.7 -4.0999999999999996 -4.0999999999999996 -20 0 -9.6 -2.2999999999999998 -1.8 0 -5.2 -,327.9 -17.5 0 0 -69.3 -,230.4 0 0.8 0 -2.5 -,262.39999999999998 Share Repurchases -4.5999999999999996 0 0 0 0 0 0 0 -,181.4 0 0 0 0 0 0 0 0 0 0 -72.900000000000006 -1.2 -10.805 Total -67.899999999999991 -3.7 -4.0999999999999996 -4.0999999999999996 -20 0 -9.6 -2.2999999999999998 -183.20000000000002 0 -5.2 #REF! #REF! 0 0 -69.3 -,230.4 0 0.8 -72.900000000000006 -3.7 -,273.20499999999998 Cash Adjustments #REF! #REF! #REF! -6.3 -3.9 -1.8 -4.9000000000000004 -1.9 -27.4 -18.5 -0.1 -48 -94.1 -160.79999999999998 -303.10000000000002 -606.1 -1164.1999999999998 -2234.2999999999997 -4307.7999999999993 -8312.4999999999982 -16018.899999999998 -30873.599999999991 -59512.899999999987 -114717.99999999997 -221123.49999999994 -426228.09999999986 #REF! #REF! #REF! 29.8 32.6 23.100000000000005 23.9 36.78 -57.78 55.480000000000004 40.140000000000008 19.800000000000011 -359.29999999999995 -31.399999999999977 -187.90000000000003 #REF! #REF! -2144.6999999999998 -4162.9999999999991 -8444.6999999999989 -16218.699999999997 -30715.23599999999 -59390.099999999984 -114764.39999999997 -221002.29999999993 -426656.30999999988 DOJ settlement -35 Changes in working capital #REF! #REF! #REF! 12.8 -12.6 -28 -7.9 -14.4 16.8 -20 -18 -35.6 -56.8 -130.39999999999998 -240.79999999999998 -463.59999999999997 -891.59999999999991 -1726.3999999999999 -3322.3999999999996 -6403.9999999999991 -12344.399999999998 -23797.199999999997 -45867.999999999993 -88413.599999999977 -170423.19999999995 -328501.99999999988 Cash Flow from Operations #REF! #REF! #REF! #REF! #REF! -4.899999999999995 15.999999999999998 22.380000000000003 -40.980000000000004 35.480000000000004 22.140000000000008 -15.79999999999999 -416.09999999999997 -161.79999999999995 -428.70000000000005 #REF! #REF! -3871.0999999999995 -7485.3999999999987 -14848.699999999997 -28563.099999999995 -54512.435999999987 -105258.09999999998 -203177.99999999994 -391425.49999999988 -755158.30999999982 Capital expenditures - routine #REF! #REF! #REF! -4.0999999999999996 -2.6 -1.6 -0.1 -2.4 -1.4 -0.3 -1.2 -5.3 -8.1999999999999993 -15 -29.7 -58.2 -111.1 -214 -413 -796.3 -1534.4 -2957.7 -5701.4 -10989.8 -21183.3 -40832.199999999997 Required debt repayments #REF! #REF! #REF! #REF! 0 -1.3 -1.3 -1.3 -1.3 -1.6 -1.3 -5.5 -9.6999999999999993 -18.100000000000001 -34.6 -67.900000000000006 -130.30000000000001 -250.90000000000003 -483.70000000000005 -932.80000000000007 -1797.7000000000003 -3465.1000000000004 -6679.3000000000011 -12874.900000000001 -24817.000000000004 -47836.3 Free cash flow #REF! #REF! #REF! #REF! #REF! -7.7999999999999945 14.599999999999998 18.680000000000003 -43.68 33.580000000000005 19.640000000000008 -26.599999999999991 -433.99999999999994 -194.89999999999995 -493.00000000000006 #REF! #REF! -4335.9999999999991 -8382.0999999999985 -16577.799999999996 -31895.199999999997 -60935.235999999983 -117638.79999999997 -227042.69999999992 -437425.79999999987 -843826.80999999982 Capital Deployment Acquisitions -63.3 -3.7 -4.0999999999999996 -4.0999999999999996 -20 0 -9.6 -33.700000000000003 -63.300000000000004 -106.60000000000001 -213.20000000000002 -416.80000000000007 -799.90000000000009 -1536.5000000000002 -2966.4000000000005 -5719.6000000000013 -11022.400000000001 -21244.9 -40953.300000000003 -78940.200000000012 -152160.80000000002 -293299.20000000007 Share Repurchases -4.5999999999999996 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Total -67.899999999999991 -3.7 -4.0999999999999996 -4.0999999999999996 -20 0 -9.6 -33.700000000000003 -63.300000000000004 -106.60000000000001 -213.20000000000002 -416.80000000000007 -799.90000000000009 -1536.5000000000002 -2966.4000000000005 -5719.6000000000013 -11022.400000000001 -21244.9 -40953.300000000003 -78940.200000000012 -152160.80000000002 -293299.20000000007

Income Statement Adjustments (1) The financial results for the three-month periods ended September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021 and September 30, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Other (income) expense, net includes ~$31.1 million gain on Medalogix equity method investment for the three-month period ended June 30, 2021. $000s Income Statement Line Item Q414 2Q15 3Q15 4Q15 1Q16 2Q16 2Q17 3Q17 2Q18 3Q20 4Q20 1Q21 2Q21 3Q21 Revenue Contingency accrual Net Service Revenue $0 $0 $0 $-6,541 $0 Other Operating Income CARES Act & State COVID-19 grants Other Operating Income -4,812 -6,780 -8,701 -4,603 4 Cost of Service COVID-19 costs Cost of Service, Excluding Depreciation & Amortization 4389 6568 8480 4464 3513 ` Severance - reduction in staffing levels Cost of Service, Excluding Depreciation & Amortization -550 0 0 0 0 G&A Acquisition and integration costs G&A, Salaries and benefits 1267 507 196 510 1071 Severance - reduction in staffing levels G&A, Salaries and benefits 0 0 0 0 0 COVID-19 costs G&A, Salaries and benefits 44 45 25 9 60 Acquisition and integration costs G&A, Other 1046 1202 183 294 440 2359 727 1003 1783 1686 COVID-19 costs G&A, Other 278 132 192 151 139 Pre-acquisition legal settlement G&A, Other 0 0 0 1825 0 Other Items Asset impairment (acquired names) Asset impairment 0 4152 0 0 0 Interest component of certain items Interest expense 558 464 517 469 451 Other (income) expense, net (2) Total other (expense) income, net -3945 -1563 436 70 -1692 -115 -1635 -39 0 0 ,-31,077 -66 Total -214 3748 2996 -2503 2614 447 27732 -586 -652 $3,494 $5,815 $1,712 $,-33,010 $6,858 EPS Impact -0.01 0.12 9.1387688013335661E-2 0.02 0.14000000000000001 0.1 0.49 0.13 $0.02 $0.08 $0.13 $0.04 $-0.74 $0.17

2021 Guidance

Amedisys 2021 Updated Guidance Updated Revenue, EBITDA and EPS guidance ranges for FY 2021 reflect COVID impact and include Contessa and VNA acquisitions ($M except for EPS) AMED Core Performance Impact of Contessa and VNA Updated AMED Guidance Post Q2 Updated AMED Guidance Post Q3 Adjusted Revenue $2,230 - $2,245 $11 - $14 $2,241 - $2,259 $2,200 - $2,205 Adjusted EBITDA $315 - $320 ($14) – ($12) $301 - $308 $296 - $298 Adjusted EPS $6.37 - $6.49 ($0.34) – ($0.31) $6.03 - $6.18 $5.88 - $5.93 Guidance Disclaimer COVID-19 has impacted the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and Contessa. We are basing our guidance on our current operating environment. COVID-19 continues to evolve in both the disease itself as well as disruptions to the healthcare systems and the economy. Any future regulations or government interventions, spike in clinicians and BD staff on quarantine, staffing shortages due to current and proposed federal, state and local vaccine mandates, reduction in elective procedures, change in patient behavior and further decline in senior living occupancy could impact our ability to achieve this guidance. Note: Adjusted numbers are ex-CARES Act funds

Environmental, Social, Governance (E.S.G.) Considerations

Environmental, Social, Governance (E.S.G.) Considerations Sustainable, high-quality, patient focused, home-based care model Environmental, Social, Governance Environmental Amedisys is dedicated to the sustainability of our business and the communities in which we serve Environmental health has a strong correlation with physical health A greener fleet – newer vehicles, in circulation for a shorter time, optimize fuel usage. Sophisticated scheduling practices reduce our clinicians’ driving time and fuel usage helping to minimize our carbon footprint Virtual care centers, along with flexible working schedules and locations, have created fewer emissions Social Amedisys strives to create an organizational culture and climate in which every individual is valued, all team members have a sense of belonging with one another and to the organization and feel empowered to do their best work Provider of Home Health and Hospice services to frail, elderly patients in their most preferred care location – their homes Highest quality Home Health company as measured by Quality of Patient Care Star scores (4.33 Stars) The Amedisys Foundation was formed to provide support to our patients and employees. The Amedisys Foundation has two funds: the Patients’ Special Needs Fund and the Amedisys Employees 1st Fund. The Patients’ Special Needs Fund provides financial assistance to our home health, hospice and personal care patients during a difficult time Governance Amedisys has a culture of compliance starting with oversight from the Board of Directors and cascading down to the care center level Our Board of Directors operates several sub-committees including: Quality Committee Compliance Committee Audit Committee Compensation Committee Nominating & Corporate Governance Committee Nominating and Corporate Governance Committee oversees our strategy on corporate social responsibility, including evaluating the impact of Company practices on communities and individuals, and develops and recommends to our Board of Directors for approval matters relating to the Company’s corporate social responsibility and ESG considerations

XML

Document and Entity Information	Nov. 02, 2021
Cover [Abstract]
Entity Registrant Name	AMEDISYS INC
City Area Code	(225) 292-2031 or (800)
Amendment Flag	false
Entity Central Index Key	0000896262
Document Type	8-K
Document Period End Date	Nov. 02, 2021
Entity File Number	0-24260
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	11-3131700
Entity Address, Address Line One	3854 American Way
Entity Address, Address Line Two	Suite A
Entity Address, City or Town	Baton Rouge
Entity Address, State or Province	LA
Entity Address, Postal Zip Code	70816
Local Phone Number	467-2662
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	AMED
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false